

Staying at the Forefront of HER2- and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer

Sunday, 15 September 2024

13:00 – 14:30 CEST

Alicante Auditorium, Hall 3,
Fira Barcelona Gran Via, Barcelona, Spain

Course Director



Peter Schmid, FRCP, MD, PhD
Centre for Experimental Cancer Medicine
St Bartholomew Hospital
London, United Kingdom

Faculty



Cristina Saura Manich, MD, PhD
Vall d'Hebrón University Hospital
Vall d'Hebrón Institute of Oncology (VHIO)
Barcelona, Spain



Aditya Bardia, MD, MPH
UCLA
Los Angeles, California, USA



PeerVoice is an EBAC® accredited provider since 2022. This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for up to 1.0 hour(s) of external CE credit(s). Each participant should claim only time that has been spent in the educational activity.

The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on substantial equivalency of accreditation systems with EBAC®. Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

© 2010–2024, PeerVoice

Agenda

13:00

Welcome and Introduction
Peter Schmid, FRCP, MD, PhD

13:05

Treating HER2- and HR-Positive Breast Cancers: An Era of Impressive Advances
Peter Schmid, FRCP, MD, PhD

13:20

The Next Advances in ADC Strategies for HER2-Positive Metastatic Breast Cancer
Cristina Saura Manich, MD, PhD

13:40

HR-Positive Metastatic Breast Cancer: The Latest Updates and Clinical Implications of HER2- and TROP2-Directed ADCs
Aditya Bardia, MD, MPH

14:00

ADCs for High-Risk HER2-Positive Early Breast Cancer: Are the Data Showing Potential?
Entire Panel

14:10

Ask-the-Faculty Roundtable Discussion and Take-Home Messages
Entire Panel

PeerVoice